Business Context and Reporting Period
This Form 8-K was filed by Bionano Genomics, Inc. (BNGO) on May 14, 2021. The report discloses the termination of a material definitive agreement regarding the company's debt obligations.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial metric disclosed is the debt payoff amount.
- Total Debt Payoff: Approximately $17.1 million.
- Payoff Components: Includes principal, interest, fees, reimbursement of expenses, and other items.
- Lenders: East West Bank and Innovatus Life Sciences Lending Fund I, LP.
Material Changes
On May 14, 2021, the Company executed a payoff letter to repay in full all amounts due under the Loan and Security Agreement dated March 14, 2019 (as amended). This action terminated all commitments and obligations under the agreement. The filing references prior amendments to the loan agreement filed in 2019, 2020, and 2021.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the debt termination. The document states that the summary of the Loan Agreement is subject to the full text of the agreement and its amendments filed as exhibits to previous reports.
Investor Verification Checklist
- Verify the exact breakdown of the $17.1 million payoff between principal and interest/fees in the referenced Form 10-Q filed May 13, 2021.
- Confirm the company's remaining cash balance post-payoff to assess liquidity impact.
- Review the specific terms of the Loan Agreement and its four amendments (filed as Exhibits 10.2, 10.1, 10.49, 10.4, and 10.44 in prior filings) to understand the full history of the obligation.